Tag: intelligence

LUXEMBOURG, July 20, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation blockchain protocol, today officially launched Stage 1 of its public presale, introducing a platform that combines programmable AI smart contracts with zk-SNARK-powered privacy infrastructure. With a hybrid Proof-of-Yield (PoY) and Proof-of-Stake (PoS) consensus design, Bitcoin Swift aims to bring a new level of intelligence and security to decentralized finance.

Lion City, Singapore, July 19, 2025 (GLOBE NEWSWIRE) -- As the global blockchain sector accelerates investments into infrastructure, energy-efficient solutions, and artificial intelligence integration, cloud mining has gained significant traction among institutional and retail participants. Among the companies shaping this shift is AIXA Miner, a technology-forward platform that has steadily built a reputation for secure, scalable, and clean-powered mining solutions.

LONDON, UK, July 19, 2025 (GLOBE NEWSWIRE) -- In a year defined by heightened attention to security and transparency across digital asset infrastructure, AIXA Miner has launched a pilot initiative to integrate predictive artificial intelligence into its global mining operations. The move reflects an industry-wide shift toward more proactive security architecture, particularly as cloud mining platforms increasingly come under the lens of institutional due diligence and regulatory expectations.

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –